Novartis' Jennifer Sheng on Solubility Modelling & the Future of Solubilisation
Poor solubility is an obvious barrier to advancing potentially efficacious drug candidates. In this interview Jennifer Sheng, Fellow at Novartis, discusses the most efficient approaches for measuring solubility, why solubility remains a critical challenge in formulation development and how solubility modelling can reduce the R&D timeline. Have Your Say Rate this feature and give us your feedback in the comments section below
To continue reading this story
Please note: That all fields marked with an asterisk (*) are required.